Human immunodeficiency virus testing in patients with invasive cervical carcinoma: a prospective trial of the gynecologic oncology group

2006 ◽  
Vol 16 (2) ◽  
pp. 660-663 ◽  
Author(s):  
A. CALKINS ◽  
F.B. STEHMAN ◽  
B. BUNDY ◽  
J.A. BENDA ◽  
R.S. MANNEL ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cervical Carcinoma ◽  
Gynecologic Oncology ◽  
Prospective Trial ◽  
Human Immunodeficiency Virus Testing ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Invasive Cervical Carcinoma ◽  
Immunodeficiency Virus ◽  
Virus Testing

scholarly journals Prenatal Human Immunodeficiency Virus Testing and Patient Management by Obstetricians in a High Seroprevalence Community

1994 ◽  
Vol 2 (1) ◽  
pp. 25-29
Author(s):  
William R. Robinson ◽  
Michael Fleischer
Keyword(s):  
Risk Factors ◽  
Human Immunodeficiency Virus ◽  
Management Strategies ◽  
Prenatal Testing ◽  
Human Immunodeficiency Virus Testing ◽  
Hiv Positive ◽  
High Seroprevalence ◽  
Immunodeficiency Virus ◽  
Hiv Seropositive ◽  
Virus Testing

Objective: In order to determine the practice habits of obstetricians concerning frequency of prenatal human immunodeficiency virus (HIV) testing and management strategies for HIV-seropositive obstetric patients, we conducted a telephone survey of practicing obstetricians over a 3-month period.Methods: In the New Orleans metropolitan area, 71/104 (68%) obstetricians participated and completed the survey.Results: Of these obstetricians, 43/71 (60.6%) test all new obstetric patients for HIV; 64/71 (84.5%) routinely ask the patients about risk factors for infection; and 28/71 (39.4%) have actually cared for an HIV-positive patient in their practice. Those obstetricians who routinely tested for HIV were more likely to have personally managed an infected patient and more likely to ask about risk factors. The number of obstetricians who would manage infected patients without consultative assistance was 8/71 (11%).Conclusions: We concluded that obstetricians in this community have largely accepted routinely offered prenatal testing and risk assessment, but they have assumed a relatively small role in risk reduction counseling and treatment.

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.

1985 ◽  
Vol 3 (8) ◽  
pp. 1079-1085 ◽  
Author(s):  
P Bonomi ◽  
J A Blessing ◽  
F B Stehman ◽  
P J DiSaia ◽  
L Walton ◽  
...  
Keyword(s):  
Complete Remission ◽  
Remission Rate ◽  
Gynecologic Oncology ◽  
Prospective Trial ◽  
Response Duration ◽  
Response Rates ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Free Interval ◽  
Remission Rates

The Gynecologic Oncology Group has conducted a randomized prospective trial comparing cisplatin 50 mg/m2 every 21 days (regimen 1), 100 mg/m2 every 21 days (regimen 2), and cisplatin 20 mg/m2 for five consecutive days repeated every 21 days (regimen 3). Four hundred ninety-seven evaluable patients have been accrued on this study. The response rates were 20.7%, 31.4%, and 25.0%, for regimens 1, 2, and 3, respectively; the complete remission rates were 10.0%, 12.7%, and 8.6% for regimens 1, 2, and 3, respectively. The median duration of response ranged from 3.9 to 4.8 months, the median progression-free interval from 3.7 to 4.6 months, and the median survival time from 6.1 to 7.1 months. The difference in response rates for regimens 1 and 2 is statistically significant (P = .015) but less than the magnitude originally considered clinically significant. The differences in complete remission rates, response duration, progression-free interval, and survival times are not statistically significant. The following types of toxicity were observed: serum creatinine level greater than 2 mg/dL and/or BUN level greater than 40 mg/dL was 7%, 14%, and 17% on regimens 1, 2, and 3, respectively; leukocyte count less than 4,000/microL was 27%, 44%, and 41% on regimens 1, 2, and 3, respectively. Nausea and vomiting occurred in 74 patients (83%). The regimen consisting of a 100-mg/m2 single dose has produced a statistically significant higher response rate than the 50 mg/m2 regimen while producing no appreciable differences in complete remission rate, response duration, progression-free interval, or survival. In addition, the higher dose regimen was associated with greater myelosuppression and nephrotoxicity.

Improving Human Immunodeficiency Virus Testing Rates with an Electronic Clinical Reminder

2012 ◽  
Vol 125 (3) ◽  
pp. 240-242 ◽  
Author(s):  
Daniel G. Federman ◽  
Jeffrey D. Kravetz ◽  
Luz S. Vasquez ◽  
Sheldon M. Campbell
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Testing ◽  
Clinical Reminder ◽  
Immunodeficiency Virus ◽  
Virus Testing
Sign in / Sign up

Export Citation Format

Share Document